Navigation Links
Metabolex Appoints Donald Hill as Chief Financial Officer
Date:4/14/2008

HAYWARD, Calif., April 14 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions. Mr. Hill joins Metabolex following more than 20 years in finance and corporate development management roles at Merck & Co., Inc., most recently as Assistant Treasurer, Global Capital Markets.

"The appointment of Don expands the depth of our already strong management team," said President and Chief Executive Officer Harold Van Wart, Ph.D. "Don's experience as a leader in a well respected, financially sophisticated pharmaceutical company, his experience in business development, and his strong analytical skills and strategic financial vision will be critical for us as we expand our product pipeline and move our clinical product candidates towards commercialization. With the company's four clinical product candidates and active discovery and preclinical development programs, Don's skills in financial planning and strategic product development will be invaluable."

Mr. Hill is a Chartered Financial Analyst (CFA), and holds a B.A. from the University of California, Berkeley and a Masters degree from the Sloan School of Management at the Massachusetts Institute of Technology.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has recently completed a Phase 2/3 trial; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which has just commenced a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Appoints New Independent Auditor
2. Indivumed Appoints Annette Kassen as Vice President Clinical Research
3. ADVENTRX Appoints Vice President of Manufacturing
4. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
5. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
6. Observant LLC Appoints Two New Directors to the Senior Management Team
7. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
8. Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
9. IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
10. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
11. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... ... June 13, 2017 , ... ... understanding the phenotype of an organism on a molecular level that is ... data processing remain major bottlenecks to biomarker discovery in clinical-based metabolomics research. ...
(Date:6/13/2017)... ... June 13, 2017 , ... ... chosen The Copley Consulting Group to facilitate and deploy Infor’s CloudSuite Industrial ... manufacturing operations and strategic initiatives to increasing customer demands. , “The clients ...
(Date:6/13/2017)... Va. (PRWEB) , ... June 13, 2017 , ... ... Ph.D. will keynote the American Chemical Society (ACS) Green Chemistry Institute’s ... at 8:45 a.m. EST. Dr. Feehery will address other business leaders, policy makers, ...
(Date:6/12/2017)... , ... June 12, 2017 , ... ... safety analytics products and services, today announced that Paul Barrow has joined the ... helping to optimize their signal detection processes and methodologies by leveraging capabilities in ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):